1. Home
  2. Faculty

Andrew Bellizzi, MD

Clinical Professor of Pathology

Introduction

Interests: Diagnosis, classification, and etiopathogenesis of human disease (especially gastrointestinal, neuroendocrine, hereditary, liver, and pancreatobiliary).

Current Positions

  • Clinical Professor of Pathology
  • Director of GI Pathology, HCCC
  • Co-Director of Immunopathology Laboratory
  • Director of GI Pathology Fellowship Track, Pathology

Education

  • BA, University of Notre Dame
  • BS, University of Notre Dame
  • MD, Northwestern University, Feinberg School of Medicine
  • Resident in Pathology, AP/CP, University of Virginia Health System
  • Fellow in Gastrointestinal/Liver Pathology, The Ohio State University Medical Center

Center, Program and Institute Affiliations

Licenses & Certifications

  • State of Iowa Medical License, Iowa Board of Medicine, Iowa
  • Anatomic and Clinical Pathology, American Board of Pathology

Selected Publications

  • Borbon LC, Sherman SK, Breheny PJ, Chandrasekharan C, Menda Y, Bushnell D, Bellizzi AM, Ear PH, O'Dorisio MS, O'Dorisio TM, Dillon JS, Howe JR. (2024) Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2024 Nov 6. doi: 10.1245/s10434-024-16463-7 PMID: 39505730
  • Tu BH, Khalyfa A, Bellizzi AM, Tanaka T. (2024) Hepatocellular Carcinoma with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Absence of Cirrhosis. ACG Case Rep. May 9; 11(5):e01348. DOI: 10.14309/crj.0000000000001348. PMID: 38725478. PMCID: PMC11081597
  • Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. (2024) Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. Apr 29; DOI: 19,3322.caac.21840. PMID: 38685134.
  • Goldsmith JD, Troxell ML, Roy-Chowdhuri S, Colasacco CF, Edgerton ME, Fitzgibbons PL, Fulton R, Haas T, Kandalaft PL, Kalicanin T, Lacchetti C, Loykasek P, Thomas NE, Swanson PE, Bellizzi AM. (2024) Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update. Arh Pathol Lab Med. Jun 1; 148(6):e111-e153. DOI: 10.5858/arpa.2023-0483-CP. PMID: 38391878.
  • Pietan L, Vaughn H, Howe JR, Bellizzi AM, Smith BJ, Darbro B, Braun T, Casavant T. (2023) Prioritization of Fluorescence In Situ Hybridization (FISH) Probes for Differentiating Primary Sites of Neuroendocrine Tumors with Machine Learning. Int J Mol Sci. Dec 12; 24(24):17401. DOI: 10.3390/ijms242417401. PMID: 48139230. PMCID: PMC10743810.
  • Desai N, Kudose S, Remotti HE, Del Portillo A, Fazlollahi L, Lee MJ, Xiong Y, Moreira RK, Salomao M, Fiel MI, Gonzalez RS, Misdraji J, Gill RM, Hart J, Kleiner DE, Drebber U, Bellizzi AM, Lagana SM. (2024) Erythrophagocytosis is not a reproducible finding in liver biopsies, and is not associated with clinical diagnosis of hemophagocytic lymphohistiocytosis. Virchows Arch. Jan; 484(1):61-69. DOI: 10.1007/s00428-023-03683-7. PMID: 37924345.
  • Skopec Z, Alsawas M, Maxwell T, Pelletier D, Brown-Joel Z, Bellizzi A, Liu V. (2024) Assessment of specificity of dermatopathologic criteria for IgG4-related skin disease. J Cutan Pathol. Feb; 51(2):163-169. DOI: 10.1111/cup.14548. PMID: 37853944.
  • Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. (2023) Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol. Nov 10; 41(32):5049-5067. DOI: 10.1200/JCO.23.01529. PMID: 37774329.
  • Bellizzi AM. (2023) p53 as Exemplar Next-Generation Immunohistochemical Marker: A Molecularly Informed, Pattern-Based Approach, Methodological Considerations, and Pan-Cancer Diagnostic Applications. Appl Immunohistochem Mol Morphol. Aug 1; 31(7):507-530. DOI: 10.1097/PAI.0000000000001144. PMID: 37471633.